Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition
Activating mutations of the non-receptor protein tyrosine phosphatase SHP2 can cause cancer. Here the authors present the crystal structure of SHP2E76K, the most frequent cancer-associated SHP2 mutation, which adopts an open-state structure and show that the allosteric inhibitor SHP099 can revert SH...
Guardado en:
Autores principales: | Jonathan R. LaRochelle, Michelle Fodor, Vidyasiri Vemulapalli, Morvarid Mohseni, Ping Wang, Travis Stams, Matthew J. LaMarche, Rajiv Chopra, Michael G. Acker, Stephen C. Blacklow |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d0fced2ac7bd48d8ba126a11fc5bed5f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state
por: Paolo Calligari, et al.
Publicado: (2021) -
Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2
por: Ricardo A. P. Pádua, et al.
Publicado: (2018) -
SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms
por: Ye Wang, et al.
Publicado: (2021) -
Molecular features underlying differential SHP1/SHP2 binding of immune checkpoint receptors
por: Xiaozheng Xu, et al.
Publicado: (2021) -
Initiating the reorganization procedure according to the law on bankruptcy: Reorganization vs. prepackaged reorganization plan
por: Kajević Amina
Publicado: (2021)